Literature DB >> 25830761

High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria.

Nicolas Pallet1, Iadh Mami2, Caroline Schmitt3, Zoubida Karim4, Arnaud François5, Marion Rabant6, Dominique Nochy7, Laurent Gouya3, Jean-Charles Deybach3, Yichum Xu-Dubois8, Eric Thervet9, Hervé Puy3, Alexandre Karras9.   

Abstract

Acute intermittent porphyria (AIP) is a genetic disorder of the synthesis of heme caused by a deficiency in hydroxymethylbilane synthase (HMBS), leading to the overproduction of the porphyrin precursors δ-aminolevulinic acid and porphobilinogen. The aim of this study is to describe the clinical and biological characteristics, the renal pathology, and the cellular mechanisms of chronic kidney disease associated with AIP. A total of 415 patients with HMBS deficiency followed up in the French Porphyria Center were enrolled in 2003 in a population-based study. A follow-up study was conducted in 2013, assessing patients for clinical, biological, and histological parameters. In vitro models were used to determine whether porphyrin precursors promote tubular and endothelial cytotoxicity. Chronic kidney disease occurred in up to 59% of the symptomatic AIP patients, with a decline in the glomerular filtration rate of ~1 ml/min per 1.73 m(2) annually. Proteinuria was absent in the vast majority of the cases. The renal pathology was a chronic tubulointerstitial nephropathy, associated with a fibrous intimal hyperplasia and focal cortical atrophy. Our experimental data provide evidence that porphyrin precursors promote endoplasmic reticulum stress, apoptosis, and epithelial phenotypic changes in proximal tubular cells. In conclusion, the diagnosis of chronic kidney disease associated with AIP should be considered in cases of chronic tubulointerstitial nephropathy and/or focal cortical atrophy with severe proliferative arteriosclerosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25830761     DOI: 10.1038/ki.2015.97

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  43 in total

1.  Lipocalin 2 is essential for chronic kidney disease progression in mice and humans.

Authors:  Amandine Viau; Khalil El Karoui; Denise Laouari; Martine Burtin; Clément Nguyen; Kiyoshi Mori; Evangéline Pillebout; Thorsten Berger; Tak Wah Mak; Bertrand Knebelmann; Gérard Friedlander; Jonathan Barasch; Fabiola Terzi
Journal:  J Clin Invest       Date:  2010-11       Impact factor: 14.808

2.  Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling.

Authors:  Guobin He; Debanjan Dhar; Hayato Nakagawa; Joan Font-Burgada; Hisanobu Ogata; Yuhong Jiang; Shabnam Shalapour; Ekihiro Seki; Shawn E Yost; Kristen Jepsen; Kelly A Frazer; Olivier Harismendy; Maria Hatziapostolou; Dimitrios Iliopoulos; Atsushi Suetsugu; Robert M Hoffman; Ryosuke Tateishi; Kazuhiko Koike; Michael Karin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

3.  Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria.

Authors:  H Puy; J C Deybach; J Lamoril; A M Robreau; V Da Silva; L Gouya; B Grandchamp; Y Nordmann
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

4.  Rapamycin inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression and stability.

Authors:  Nicolas Pallet; Eric Thervet; Delphine Le Corre; Bertrand Knebelmann; Patrick Nusbaum; Céline Tomkiewicz; Paul Meria; Jean-Pierre Flinois; Philippe Beaune; Christophe Legendre; Dany Anglicheau
Journal:  Kidney Int       Date:  2005-06       Impact factor: 10.612

5.  Interleukin-6 regulation of transforming growth factor (TGF)-beta receptor compartmentalization and turnover enhances TGF-beta1 signaling.

Authors:  Xiao Liang Zhang; Nicholas Topley; Takafumi Ito; Aled Phillips
Journal:  J Biol Chem       Date:  2005-01-20       Impact factor: 5.157

6.  Reversible MRI findings of porphyric encephalopathy. A report of two cases.

Authors:  A Soysal; P Dogan; C Dayan; B G Caliskan; B Arpaci
Journal:  Neuroradiol J       Date:  2008-12-17

7.  Could attacks of abdominal pain in cases of acute intermittent porphyria be due to intestinal angina?

Authors:  F Lithner
Journal:  J Intern Med       Date:  2000-03       Impact factor: 8.989

8.  Caspase activation regulates the extracellular export of autophagic vacuoles.

Authors:  Isabelle Sirois; Jessika Groleau; Nicolas Pallet; Nathalie Brassard; Katia Hamelin; Irène Londono; Alexey V Pshezhetsky; Moise Bendayan; Marie-Josée Hébert
Journal:  Autophagy       Date:  2012-06-01       Impact factor: 16.016

9.  Acute intermittent porphyria and chronic renal failure.

Authors:  J T Marsden; P Chowdhury; J Wang; A Deacon; N Dutt; T J Peters; I C Macdougall
Journal:  Clin Nephrol       Date:  2008-05       Impact factor: 0.975

10.  Hypertension and renal disease in patients with acute intermittent porphyria.

Authors:  C Andersson; F Lithner
Journal:  J Intern Med       Date:  1994-08       Impact factor: 8.989

View more
  24 in total

1.  Systemic inflammation in acute intermittent porphyria: a case-control study.

Authors:  E Storjord; J A Dahl; A Landsem; H Fure; J K Ludviksen; S Goldbeck-Wood; B O Karlsen; K S Berg; T E Mollnes; E W Nielsen; O-L Brekke
Journal:  Clin Exp Immunol       Date:  2016-12-15       Impact factor: 4.330

2.  Effects of hemin and hemodialysis in a patient with acute intermittent porphyria and renal failure.

Authors:  Shirin Attarian; Chunli Yu; Karl E Anderson; Ellen W Friedman
Journal:  Blood Adv       Date:  2017-06-05

Review 3.  Hepatic porphyria: A narrative review.

Authors:  Sumant Arora; Steven Young; Sudha Kodali; Ashwani K Singal
Journal:  Indian J Gastroenterol       Date:  2016-10-31

4.  A Variant of Peptide Transporter 2 Predicts the Severity of Porphyria-Associated Kidney Disease.

Authors:  Dimitri Tchernitchko; Quentin Tavernier; Jérôme Lamoril; Caroline Schmitt; Neila Talbi; Said Lyoumi; Anne-Marie Robreau; Zoubida Karim; Laurent Gouya; Eric Thervet; Alexandre Karras; Hervé Puy; Nicolas Pallet
Journal:  J Am Soc Nephrol       Date:  2016-12-28       Impact factor: 10.121

Review 5.  Acute hepatic porphyrias: Recommendations for evaluation and long-term management.

Authors:  Manisha Balwani; Bruce Wang; Karl E Anderson; Joseph R Bloomer; D Montgomery Bissell; Herbert L Bonkovsky; John D Phillips; Robert J Desnick
Journal:  Hepatology       Date:  2017-09-04       Impact factor: 17.425

Review 6.  The acute hepatic porphyrias.

Authors:  Bruce Wang
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

7.  Endothelial Dysfunction in Acute Hepatic Porphyrias.

Authors:  Andrea Ricci; Gilda Sandri; Matteo Marcacci; Elena Di Pierro; Francesca Granata; Chiara Cuoghi; Stefano Marchini; Antonello Pietrangelo; Paolo Ventura
Journal:  Diagnostics (Basel)       Date:  2022-05-24

Review 8.  Novel treatment options for acute hepatic porphyrias.

Authors:  Bruce Wang
Journal:  Curr Opin Gastroenterol       Date:  2021-05-01       Impact factor: 2.741

9.  Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.

Authors:  Paolo Ventura; Herbert L Bonkovsky; Laurent Gouya; Paula Aguilera-Peiró; D Montgomery Bissell; Penelope E Stein; Manisha Balwani; D Karl E Anderson; Charles Parker; David J Kuter; Susana Monroy; Jeeyoung Oh; Bruce Ritchie; John J Ko; Zhaowei Hua; Marianne T Sweetser; Eliane Sardh
Journal:  Liver Int       Date:  2021-11-16       Impact factor: 8.754

10.  Renal Function Decline With Small Interfering RNA Silencing Aminolevulinic Acid Synthase 1 (ALAS1).

Authors:  Hélène Lazareth; Antoine Poli; Yohan Bignon; Arienne Mirmiran; Marion Rabant; Raphaël Cohen; Caroline Schmitt; Hervé Puy; Alexandre Karras; Laurent Gouya; Nicolas Pallet
Journal:  Kidney Int Rep       Date:  2021-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.